NCT02442349 - Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

June 22, 2015

Primary Completion Date

March 4, 2016

Study Completion Date

December 31, 2025

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

AZD9291

Once daily tablet 80 mg

Trial Locations (30)

2217

Research Site, Kogarah

4102

Research Site, Woolloongabba

6009

Research Site, Nedlands

6351

Research Site, Seoul

10408

Research Site, Goyang-si

13620

Research Site, Seongnam-si

100021

Research Site, Beijing

100142

Research Site, Beijing

100730

Research Site, Beijing

130000

Research Site, Changchun

150049

Research Site, Harbin

200030

Research Site, Shanghai

200032

Research Site, Shanghai

210009

Research Site, Nanjing

250117

Research Site, Jinan

310003

Research Site, Hangzhou

310006

Research Site, Hangzhou

310022

Research Site, Hangzhou

350014

Research Site, Fuzhou

400038

Research Site, Chongqing

400042

Research Site, Chongqing

430022

Research Site, Wuhan

430030

Research Site, Wuhan

450008

Research Site, Zhengzhou

570311

Research Site, Haikou

610041

Research Site, Chengdu

710032

Research Site, Xi'an

710038

Research Site, Xi'an

CN-200433

Research Site, Shanghai

05505

Research Site, Seoul